Sysmex Nederland
Menu

Colorectal cancer

Earlier recognition. Better survival rates. Synergy in expertise.

Over 400,000 of new cases of colorectal cancer are diagnosed in Europe each year. Yet early recognition, individualising cancer therapy, and using less invasive diagnostics are leading to improved prognoses and greater quality of life. Identifying the cancer early on is especially important for therapeutic success. Screening – both symptomatic and especially large-scale – is essential.

Everything we offer is designed to help clinicians, laboratories and physicians that adress screening, diagnosis and therapy of colorectal cancer disease.

Screening

The quantitative FOB Gold FIT (Faecal immunological testing) screening test delivers more reliable results than the standard qualitative test. Extremely flexible, it can be adapted to screening programmes of any size and to laboratories with all throughputs.

Diagnostics

When determining therapy, often whether to give chemotherapy or not, the stage of the cancer is decisive. Sensitive, standardised lymph node diagnostics and the resulting nodal status are essential here. OSNA delivers the sensitivity and standardisation required and reduces false-negatives compared to classic histopathology.

Therapy

Using antibodies alongside chemotherapy has improved the overall survival of CRC patients.1 But clinicians must test stringently which patients are eligible. The OncoBEAMTM RAS CRC test uses a blood sample instead of tumour tissue and overcomes the limitations of tissue biopsies like sample availability, turnaround time and tumour heterogeneity.

Discover our solutions in colorectal cancer

Faecal Immunochemical Test For Haemoglobin (FIT)

Faecal Immunochemical Test For Haemoglobin (FIT)

OSNA

OSNA

Revealing the whole picture

OncoBEAM liquid biopsy for mutation detection

Discover our videos

Walk-Away FIT solutions for high throughput

Walk-Away FIT solutions for high throughput

Colorectal cancer monitoring

A step forward in colorectal cancer monitoring

Go Beyond Biopsy with Blood

Go Beyond Biopsy with Blood - BEAMing Digital PCR

Literature

  1. Lee J.J. et al.(2016): Options for Second-Line Treatment in Metastatic Colorectal Cancer. Clinical Advances in Hematology & Oncology, 14(1):46-54.
Copyright © Sysmex Europe GmbH. All rights reserved.
Personaliseer uw ervaring

Wij gebruiken cookies zodat u onze website optimaal kunt benutten en wij onze communicatie met u kunnen verbeteren. Wij baseren ons daarbij op uw selectie en gebruiken alleen de gegevens waarvoor u ons toestemming geeft.

* Kan de weergave van content en de gebruikerservaring beperken.
Details over cookies
Noodzakelijke cookies
Deze cookies helpen om onze website bruikbaar te maken door basisfuncties zoals paginanavigatie en toegang tot beveiligde delen van onze website te ondersteunen. Zonder deze cookies kan onze website niet goed functioneren.
Statistiekcookies
Deze cookies registreren hoe bezoekers interactief met onze website omgaan door anoniem informatie te verzamelen. Met deze informatie kunnen wij onze dienstverlening continu verbeteren.
Marketingcookies
Worden gebruikt om bezoekers op webpagina's te volgen. De bedoeling is om advertenties te tonen die relevant en aantrekkelijk zijn voor de individuele gebruiker en daarmee waardevol voor uitgevers en externe adverteerders.